323 completed, 111 unknown, 85 recruiting, 70 terminated. 697 Phase 3, 77 Phase 2.
Follow Lymphoma: new trials by email Literature Review of Lymphoma trials Research Report on Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Astragalus for Symptomatic Alleviation in High-grade Lymphoma Astragalus, Placebo - High-grade Lymphoma | Phase 3 | Not yet recruiting | Bnai Zion Medical Center | 60 | 2027-08-01 | 2026-09-30 |
| Study of Sugemalimab (or Placebo) Plus PGemOx Regimen in Participants With Extranodal NK/T-Cell Lymphoma Sugemalimab, Placebo, Pegaspargase - Extranodal NK/T-cell Lymphoma | Phase 3 | Not yet recruiting | CStone Pharmaceuticals | 150 | 2027-06-01 | 2026-05-27 |
| A Study Comparing a New Drug (Surovatamig) With Standard Radiotherapy With or Without Rituximab in Adults With Limited Stage Nodal Follicular Lymphoma Surovatamig, Involved Site Radiotherapy (ISRT), Involved-Site Radiotherapy (ISRT) + Rituximab - Follicular Lymphoma | Phase 3 | Not yet recruiting | Australasian Leukaemia and Lymphoma Group | 140 | 2027-01-12 | 2026-09-30 |
| Early Prophylactic rhTPO Administration for Thrombocytopenia Associated With EAP Regimen-Based Hematopoietic Stem Cell Mobilization rhTPO prophylaxis plus EAP stem-cell mobilization - Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma, Hematopoietic Stem Cell Mobilization | Phase 2 / Phase 3 | Not yet recruiting | The Affiliated People's Hospital of Ningbo University | 70 | 2027-01-01 | 2026-09-30 |
| A Study to Evaluate Surovatamig Combined With R-CHOP in Participants of 18 to < 80 Years of Age With Previously Untreated Large B-cell Lymphoma With IPI Score 2 to 5 Surovatamig, Rituximab, Cyclophosphamide - Large B-cell Lymphoma | Phase 3 | Not yet recruiting | AstraZeneca | 1200 | 2026-12-22 | 2026-11-02 |
| A Clinical Trial of MK-1045 With Zilovertamab Vedotin in Participants With Diffuse Large B-cell Lymphoma (MK-1045-010) MK-1045, Zilovertamab vedotin, Rituximab - Lymphoma, Large B-Cell, Diffuse, Diffuse Large B-Cell Lymphoma | Phase 2 / Phase 3 | Not yet recruiting | Merck Sharp & Dohme LLC | 470 | 2026-12-13 | 2026-11-05 |
| Testing the Addition of a New Anti-Cancer Drug, Glofitamab to Usual Chemotherapy for Burkitt and Double Hit Lymphoma Biospecimen Collection, Bone Marrow Biopsy, Carboplatin - Recurrent Burkitt Lymphoma, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements | Phase 2 / Phase 3 | Not yet recruiting | National Cancer Institute (NCI) | 271 | 2026-10-30 | 2026-08-19 |
| A Randomized, Open-Label, Multicenter Phase III Clinical Study of JS203 Plus Chemotherapy Versus Rituximab Plus Chemotherapy in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma JS203 in combination with gemcitabine and oxaliplatin, Rituximab in combination with gemcitabine and oxaliplatin - Diffuse Large B-Cell Lymphoma | Phase 3 | Recruiting | Shanghai Junshi Bioscience Co., Ltd. | 282 | 2026-10-08 | 2026-10-14 |
| A Phase 3 Study to Compare the Efficacy of ICP-248 in Combination With Orelabrutinib Versus Pirtobrutinib in Participants With Relapsed or Refractory Mantle Cell Lymphoma (r/r MCL). ICP-248, Pirtobrutinib, Orelabrutinib - Relapsed or Refractory Mantle Cell Lymphoma (MCL) | Phase 3 | Not yet recruiting | Beijing InnoCare Pharma Tech Co., Ltd. | 280 | 2026-10-01 | 2026-08-25 |
| Orelabrutinib Plus ICP 248 vs Orelabrutinib for Relapsed/Refractory Marginal Zone Lymphoma Orelabrutinib, ICP-248 - Relapsed/Refractory Marginal Zone Lymphoma (MZL) | Phase 3 | Not yet recruiting | Beijing InnoCare Pharma Tech Co., Ltd. | 292 | 2026-10-01 | 2026-10-27 |
| Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies IgPro20 - Secondary Immune Deficiency | Phase 3 | Recruiting | CSL Behring | 63 | 2026-09-15 | 2026-10-14 |
| International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020) Inotuzumab ozogamicin (INO), Blinatumomab - B-Cell Acute Lymphoblastic Leukaemia | Phase 3 | Recruiting | Charite University, Berlin, Germany | 750 | 2026-09-01 | 2026-10-26 |
| Birelentinib Plus R-CHOP in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma (TAI-SHAN19) Birelentinib, Rituximab, Cyclophosphamid - Diffuse Large B-Cell Lymphoma (DLBCL) | Phase 2 / Phase 3 | Not yet recruiting | Dizal Pharmaceuticals | 880 | 2026-09-01 | 2026-08-05 |
| Immunoglobulin Replacement Therapy (IgRT) Versus Antibiotic Prophylaxis (PA) in Patients Treated by CD19-targeted Chimeric Antigen Receptor (CAR)T Cells for a B Cell Acute Lymphoblastic Leukemia or a B Cell Lymphoma Immunoglobulin, antibiotic prophylaxis - Chimeric Antigen Receptor T-cell Therapy, B Cell Acute Lymphoblastic Leukemia (B-ALL) | Phase 3 | Not yet recruiting | Assistance Publique - Hôpitaux de Paris | 228 | 2026-09-01 | 2026-08-10 |
| Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL) Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration - Stage II T Lymphoblastic Leukemia/Lymphoma, Stage III T Lymphoblastic Leukemia/Lymphoma | Phase 2 / Phase 3 | Not yet recruiting | Children's Oncology Group | 1708 | 2026-08-28 | 2026-07-30 |
| BRIDGE-NK: Immunotherapy Versus Chemotherapy Induction Followed by Autologous HSCT in Advanced NKTCL GELAD regimen, MEDA regimen, LEAP regimen - Extranodal NK/T-cell Lymphoma | Phase 3 | Recruiting | Rong Tao | 150 | 2026-08-11 | 2026-08-13 |
| Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL NX-5948, Pirtobrutinib - B-cell Lymphoma, Chronic Lymphocytic Leukemia | Phase 3 | Recruiting | Nurix Therapeutics, Inc. | 620 | 2026-08-03 | 2026-08-31 |
| Tirzepatide in the Treatment of Cannabis Use Disorder Tirzepatide - Cannabis Use Disorder, Moderate, Cannabis Use Disorder, Severe | Phase 3 | Not yet recruiting | McMaster University | 15 | 2026-08-01 | 2026-07-01 |
| TR115 VS Investigator's Choice in Relapsed/Refractory Peripheral T/NK Cell Lymphoma TR115, Investigator's Choice - PTCL, NK T-Cell Lymphoma | Phase 3 | Not yet recruiting | Tarapeutics Science Inc. | 180 | 2026-07-30 | 2026-06-10 |
| PET Guided Dose Reduction for InvOlved Site Radiotherapy In Early sTage Unfavourable Hodgkin Lymphoma 20 Gy Involved site radiotherapy, 30 Gy Involved site radiotherapy - Hodgkin Lymphoma | Phase 3 | Recruiting | Fondazione Italiana Linfomi - ETS | 518 | 2026-07-10 | 2026-08-27 |
Showing 20 of 697. Sign in to see all of them.
Lymphoma, Follicular (218) · Lymphoma, Large B-Cell, Diffuse (185) · Lymphoma, Non-Hodgkin (183) · Hodgkin Disease (96) · Lymphoma, Mantle-Cell (86) · Burkitt Lymphoma (76) · Leukemia, Lymphocytic, Chronic, B-Cell (76) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (76) · Lymphoma, B-Cell, Marginal Zone (71) · Leukemia (63) · Multiple Myeloma (56) · Lymphoma, Large-Cell, Immunoblastic (50) · Recurrence (43) · Leukemia, Myeloid, Acute (42)
Neoplasms by Histologic Type (695) · Hemic and Lymphatic Diseases (690) · Immune System Diseases (688) · Immunoproliferative Disorders (687) · Lymphatic Diseases (687) · Lymphoproliferative Disorders (677) · Neoplasms (662) · Lymphoma, Non-Hodgkin (393) · Lymphoma, B-Cell (234) · Hematologic Diseases (170) · Pathological Conditions, Signs and Symptoms (148) · Pathologic Processes (132) · Disease Attributes (120) · Leukemia, Lymphoid (120)
Rituximab (222) · Cyclophosphamide (160) · Vincristine (144) · Doxorubicin (140) · Prednisone (122) · Etoposide (71) · Radiotherapy (56) · Cytarabine (55) · Methotrexate (50) · Dexamethasone (46) · Bendamustine Hydrochloride (45) · Lenalidomide (41) · Filgrastim (36) · Bleomycin (35) · Prednisolone (32)
Hoffmann-La Roche (21) · Children's Oncology Group (20) · European Organisation for Research and Treatment of Cancer - EORTC (18) · Fondazione Italiana Linfomi - ETS (14) · Pfizer (14) · Ruijin Hospital (12) · Lymphoma Study Association (11) · National Cancer Institute (NCI) (11) · Celgene (10) · M.D. Anderson Cancer Center (9) · Novartis Pharmaceuticals (9) · The Lymphoma Academic Research Organisation (9) · Alliance for Clinical Trials in Oncology (8) · Memorial Sloan Kettering Cancer Center (8) · Amgen (7)
United States (302) · France (175) · Italy (157) · China (155) · United Kingdom (152) · Germany (150) · Canada (145) · Australia (134) · Spain (134) · Belgium (128) · Poland (116) · South Korea (83) · Czechia (81) · Netherlands (80) · Israel (77)
Frederick Beddingfield, MD, PhD (4) · Mary Horowitz, MD, MS (4)
PMID 40135712, PMID 32632956, PMID 32816215, PMID 37505794, PMID 26373676, PMID 33288485, PMID 27282998, PMID 30010775, PMID 34515338, PMID 41074963, PMID 42699559, PMID 11807147, PMID 16754935, PMID 20032498, PMID 20679620, PMID 23065509, PMID 23233721, PMID 24687837, PMID 25113753, PMID 26149717, PMID 27695295, PMID 28396102, PMID 28751558, PMID 30341058, PMID 30770362, PMID 31053601, PMID 32499241, PMID 32589970, PMID 32817282, PMID 34323957, PMID 35787017, PMID 36485104, PMID 36541117, PMID 37890117, PMID 38696034, PMID 39121442, PMID 39374535, PMID 39563886, PMID 39774828, PMID 41671463, PMID 41749915, PMID 41915772, PMID 42329537, PMID 10552938, PMID 10586336, PMID 10820362, PMID 11709567, PMID 12239143, PMID 12419745, PMID 12756499
2023 (20), 2015 (7), U10CA098543 (7), 2009 (6), U10CA032102 (6), U10CA180886 (6), 2014 (5), 2016 (5), 2017 (5), 2008 (4), 2019 (4), 2025 (4), U01HL069294 (4), U10CA021115 (4), U24CA076518 (4)